Ozempic Use Among College Women Fuels Sorority Rush Culture

Glucagon-like peptide-1 (GLP-1) medications, widely known for weight loss and diabetes treatment, are reportedly seeing increased use among young adults, with anecdotal evidence pointing to their presence on college campuses and within the competitive sorority recruitment process.

A 2024 analysis in JAMA indicated that 162,439 individuals aged 18 to 25 received at least one GLP-1 prescription in 2023, with women comprising 76.4% of this demographic. These prescriptions were for both diabetes management and weight loss. Separately, the 2025 Monitoring the Future survey found that 2% of surveyed high school students reported using a prescription GLP-1 medication, and an additional 2% admitted to using one without a prescription.

A recent feature in The Cut, titled "The Secret 'Ozempidemic' on Sorority Row," suggests that GLP-1 weight-loss drugs have become integrated into campus culture at some elite universities, particularly influencing sorority recruitment.

Three female students, speaking under pseudonyms, reported using compounded semaglutide or tirzepatide to enhance their prospects during rush and to align with perceived thin beauty standards. They described significant pressure to achieve extreme thinness, fueled by social media and peer-driven weight-loss challenges.

"For many young women who have just arrived on campus, thinness feels like the ticket into the best possible college experience," one student stated. Another commented, "I didn't realize that someone who was 19 and also not super-overweight could get on it. I was like, ‘I gotta hop on.’"

A former sorority recruiter observed, "It's like, 'Well, there's no excuse for people to be fat because they could just get a GLP-1.'"

Cosmetic Shortcut

Jay Campbell, a longevity and peptide expert, noted that while these drugs are intended for metabolic health, they are being "hijacked as a cosmetic shortcut." He explained, "For someone who's metabolically dysregulated, they are a genuine medical intervention. But to a 20-year-old sorority member with a normal BMI, they look like an aesthetic hack in a syringe."

Campbell described sororities as environments built on social visibility and comparison. "When one girl drops 15 pounds in six weeks, that news spreads through the sorority house faster than any diet fad in history, because the results are fast, dramatic, and don't require the discipline of nutrition or training," he said. He added that college-aged women often have heightened body-image sensitivity, which is amplified by what he called "a full-scale social contagion."

He warned that young women may be using these medications to address pre-existing disordered relationships with food and their bodies, playing on insecurities. While GLP-1s can benefit many patients by promoting fat loss over lean mass in clinical studies for obesity, Campbell cautioned against their use by individuals without metabolic issues.

"The peptide isn't catabolic by itself – the real risk is that a healthy 20-year-old who isn't obese has far less metabolic and muscular reserve to lose from in the first place," he stated. Rapid weight loss without adequate protein and resistance training can lead to a greater proportion of lean mass loss, potentially contributing to changes in facial and body appearance, often referred to as "Ozempic face" and "Ozempic body."

Considerations for College Students

Campbell outlined five key considerations for college students contemplating GLP-1 medication:

• Medical Appropriateness: Students should question why they are taking a medication designed for a disease they do not have, if they are not obese or metabolically compromised.
• Muscle Preservation: Preventing muscle loss requires adequate protein intake and resistance training. Skipping these can result in loss of muscle tissue that is difficult to regain.
• Fertility: GLP-1 medications are not recommended during pregnancy. Semaglutide labeling advises discontinuation at least two months before a planned pregnancy. Tirzepatide can reduce the effectiveness of oral hormonal contraceptives.
• Mental Health: Discussing mental health, including depression, anxiety, eating disorders, or using food for emotional coping, is crucial. While the FDA has not found an increased risk of suicidal thoughts, patients should report any new or worsening mood symptoms.
• Long-Term Data: The long-term effects of GLP-1 use in young, healthy individuals are not yet known, as this population was not extensively studied in clinical trials. Campbell emphasized treating these powerful medications as medical interventions rather than lifestyle accessories.

Campbell concluded that while GLP-1 medications can suppress appetite, they do not address underlying metabolic issues or the reasons why a young person feels the need to lose weight. He noted that these drugs offer a pharmaceutical shortcut that bypasses the traditional behavior changes required for weight management, making them attractive to young women in highly social environments seeking rapid changes in appearance.